Phase 4
Completed N=60
MEXIDOL® in the Rehabilitation Treatment of Patients With Acute Cerebral Failure
Ischemic Stroke, Acute
Source: ClinicalTrials.gov NCT06221826 ↗
Enrolled (actual)
60
Serious AEs
0.0%
Results posted
Apr 2025
Primary outcomePrimary: Аssessment of Attentiveness and Performance — 94.9; 71.2; 75; 68.15 seconds
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
The use of metabolic modulators creates prospects for increasing the efficiency of the rehabilitation treatment of patients with acute cerebral failure
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Аssessment of Attentiveness and Performance |
94.9; 71.2; 75; 68.15; 71.7; 63 | — |
| PRIMARY Dynamics of Cognitive Status |
23.8; 22.9 | — |
| PRIMARY Severity of Depression |
7.5; 11.4 | — |
| PRIMARY Reduction in Anxiety |
2.6; 4.4 | — |
| PRIMARY Severity of Post Intensive Care Syndrome |
0.02; 0.3 | — |
| PRIMARY Dynamics of Level of Mobility |
10.3; 8.0 | — |
| PRIMARY Dynamics of the Level of Life |
2.9; 3.3 | — |
| PRIMARY Severity and Dynamics of Muscle Strength |
3.3; 2.1 | — |
| PRIMARY Systolic Cerebral Blood Flow Velocity (Vs) Using Transcranial Doppler (TCD) at Key Time Points |
72.6; 80.03; 72.23; 80.8; 74.6; 83.57 | — |
| PRIMARY Overshoot Coefficient (OC) of Systolic Cerebral Blood Flow Velocity (TCD) at Key Time Points |
1.25; 1.27; 1.26; 1.27; 1.25; 1.27 | — |
| SECONDARY Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] |
0; 0 | — |
Eligibility Criteria
Inclusion Criteria
- Acute Ischemic Stroke
- Montreal Cognitive Assessment (MoCA) test >15; ≤22
Exclusion Criteria
- Under 18 years old
- Epilepsy
- Pregnancy
- Acute failure of one or more organ systems
- Purulent-inflammatory disease of any localization
- Participating in any other clinical trial
Data sourced from ClinicalTrials.gov (NCT06221826). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.